March PBAC delivers outcome for high profile pre-funded cancer therapy

At its March meeting, surrounded by controversy following the decision to defer multiple submissions, the Pharmaceutical Benefits Advisory Committee delivered recommendations for high-profile cancer therapies, including one funded outside the PBS before it was approved, and several treatments for a chronic autoimmune disease. …